Neurocrine (NBIX) Director Shalini Sharp Converts 1,659 RSUs

What Happened

• Shalini Sharp, a director of Neurocrine Biosciences (NBIX), had 1,659 restricted stock units (RSUs) converted into 1,659 shares on May 21, 2026. The Form 4 shows an acquisition of 1,659 shares at $0.00 and a corresponding disposition of 1,659 derivative units at $0.00 — i.e., no cash proceeds are reported.

Key Details

• Transaction date: 2026-05-21 (reported same day).
• Transaction type/code: M — exercise or conversion of a derivative security (here, RSUs converting to common shares).
• Shares involved: 1,659 acquired / 1,659 derivative units disposed; price reported $0.00 for both entries.
• Shares owned after transaction: not stated in the provided filing.
• Footnotes: F1 = each RSU represents the right to one share upon vesting. F2 = the RSU award was granted on May 21, 2025 and is fully vested.
• Timeliness: Filing date equals transaction date (no late filing indicated).

Context

• This appears to be a routine vesting/conversion of RSUs into common stock rather than an open‑market purchase or sale. The simultaneous “acquired” and “disposed” entries at $0 typically reflect the conversion of the derivative award into shares (not a cash sale), and do not by themselves indicate a change in the director’s market view.